Lumateperone + Selective Serotonin Reuptake Inhibitors (Ssri) Interaction
Moderateinteraction on record
Description
CAPLYTA's moderate SERT activity may increase risk of SRI-associated adverse reactions including serotonin syndrome and hyponatremia. Increased monitoring recommended.
Mechanism
CAPLYTA's moderate serotonin transporter activity
Source: NLP:lumateperone